Item 1.02 Termination of a Material Definitive Agreement.

On May 3, 2012, Trius was notified in writing by the Defense Threat Reduction Agency, or DTRA, that it has elected not to exercise its option to continue funding under the four and one-half-year federal contract with the Company for the development of novel antibiotics directed against gram-negative bacterial pathogens, and therefore, the contract will not be extended beyond July 20, 2012. As a result, Trius has chosen to discontinue its marine natural products discovery program, which was solely funded by the DTRA contract.

Item 2.02 Results of Operations and Financial Condition.

On May 8, 2012, Trius Therapeutics, Inc. issued a press release announcing financial results for the first quarter ended March 31, 2012. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
No. Description

99.1 Trius Therapeutics, Inc. Press Release dated May 8, 2012

---